Core Viewpoint - The company, 百奥赛图-B (02315), has seen a significant stock price increase of over 12% in a single day and approximately 30% over the past three days, indicating strong market interest and confidence in its recent developments [1] Group 1: AI-Driven Antibody Drug Development - The company has completed the localization deployment of its AI-driven antibody drug development platform, which is expected to enhance collaboration with its core 千鼠万抗 plan [1] - The integration of AI systems with the 千鼠万抗 plan aims to provide global pharmaceutical companies with more efficient research tools and a richer antibody molecule library, thereby improving the efficiency of preclinical PCC molecule development [1] - This advancement is anticipated to propel the antibody discovery business into a new phase of development [1] Group 2: Collaboration with育世博 - The company has entered into an option and licensing agreement with 育世博 to systematically evaluate the BsADC project through a structured assessment mechanism [1] - This collaboration aims to accelerate the development process of the BsAD2C, a dual-target antibody drug conjugate [1]
百奥赛图-B再涨超12% 公司已完成AI驱动抗体药物研发平台的本地化部署